Edesa Biotech is a Markham, Ontario biopharmaceutical company whose entire equity story runs through one question: what is paridiprubart worth when a small balance sheet is the only thing standing between its most advanced asset and a partner? The company holds a TLR4-blocking antibody with positive survival data in acute respiratory distress syndrome, an anti-CXCL10 antibody now enrolling in a vitiligo trial, and a Phase 3-ready topical cream at the partnering stage. The share price has collapsed from a fifty-two week high of $20.32 to the current $4.73 as the market prices in the absence of a signed deal.
The third quarter of fiscal 2026 marked the operational inflection the filings have flagged since the October 2025 paridiprubart readout. Research and development spending rose to $4.0 million from $0.9 million a year earlier as the vitiligo program moved from preparation to trial execution. The company ended the period with $10.3 million of cash before raising roughly $23.1 million in a registered public offering that closed in late August, and the cash balance has more than doubled in three weeks. The equity now encodes a dilution story rather than a runway story.
The print that anchors this report carries a net loss of $5.4 million, or $0.60 per share. The accumulated deficit stood at $77.9 million at the end of the period. The going-concern note in the most recent quarterly filing is now paired with the post-quarter raise rather than left hanging. The question the next two quarters resolve is whether paridiprubart monetizes through a late-stage partnering deal, an expedited regulatory pathway, or a U.S. government platform contract, or whether the company is left funding a vitiligo trial it started while searching for an exit on its most advanced asset.